Colgate-Palmolive growth chief sells 23,376 shares
Sale prices ranged from $98.93 to $99.29, and part of the proceeds covered the option exercise price and related tax withholding.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Colgate-Palmolive Chief Growth Officer John Hazlin exercised 23,376 stock options on November 4, 2026, at $77.04 per share, acquiring 23,376 common shares, and sold 23,376 shares that day at a weighted average price of $99.1479 per share. Sale prices ranged from $98.93 to $99.29; part of the proceeds went to the issuer for the exercise price and related tax withholding. The report lists 5,544 shares held indirectly by the issuer's 401(k) Plan Trustee, and no Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F4 | 23,376 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 23,376 | $77.04 | $1.80M |
| Sale | Common Stock F2, F3 | 23,376 | $99.1479 | $2.32M |
| Holding | Common Stock | -- | -- | -- |
Footnotes (4)
- F1. Exercise of stock options awarded under the issuer's incentive compensation plan.
- F2. Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding.
- F3. Weighted average price, as these shares were sold in multiple transactions at prices ranging from $98.93 to $99.29, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2021 grant date.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
Incentive compensation plan financial
Weighted average price financial
Tax withholding financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When did John Hazlin's CL options become exercisable?
AI-generated analysis. How Rhea-AI works. Not financial advice.